GLP-1 Agonists in Older Adults

Efficacy: subgroup data

STEP-1 subgroup analysis showed participants under 65 vs 65+ achieved similar percentage weight loss on semaglutide (~14-16%)¹. SURMOUNT-1 showed the same pattern for tirzepatide across age strata³.

The SELECT cardiovascular outcomes trial in patients with prior CVD and overweight or obesity included approximately 4,400 patients aged 65+. The 20% reduction in MACE was similar across age strata, with no evidence of attenuation in the older subgroup².

Sarcopenia and fall-risk

Adults 65+ are more susceptible to clinically significant sarcopenia during weight loss. Pre-treatment grip strength and gait-speed assessment, proactive protein supplementation (1.2-1.5 g/kg/day), and resistance training prescribing are particularly important.

GLP-1-related nausea, vomiting, and reduced appetite can produce dehydration and orthostatic hypotension — both fall-risk modifiers. Slow dose titration, attention to fluid intake during dose-escalation weeks, and low threshold for dose hold reduce these risks.

Polypharmacy and drug interactions

Older adults commonly take medications whose absorption is affected by delayed gastric emptying. Levothyroxine, warfarin, oral antiarrhythmics, and immediate-release analgesics have potential for altered absorption kinetics. Most do not require dose adjustment but warrant clinical monitoring (INR, TSH, symptom response) during initiation and dose escalation&sup4;.

Patients on insulin or sulfonylureas have increased hypoglycemia risk when adding a GLP-1 RA; preemptive insulin dose reduction (10-20%) and consideration of sulfonylurea discontinuation are standard practice.

Renal function and dose adjustment

Semaglutide, liraglutide, and tirzepatide do not require dose adjustment in mild, moderate, or severe renal impairment per FDA labeling. None is removed by dialysis. The FLOW trial demonstrated benefit in T2D + CKD (eGFR 25-75)&sup5;.

Acute kidney injury risk from dehydration-related GI symptoms is a clinically relevant pathway. Patients with reduced baseline renal function and intercurrent illness should pause therapy and rehydrate.

Goal weight and stopping criteria in geriatrics

BMI-based goal weight may be less appropriate in older adults. The 'obesity paradox' suggests aggressive weight reduction in non-obese older patients may be counterproductive. AGS recommends individualizing goals to functional status, comorbidities, and patient preference rather than population-level BMI cutoffs.

Stopping criteria include unintended weight loss exceeding 10% in patients near or below normal weight, declining functional status, new falls, persistent GI symptoms, or acute kidney injury.

Related editorial coverage

• GLP-1 agonists and muscle mass
• GLP-1 agonists and bone density
• FLOW trial — semaglutide in CKD

Frequently asked questions

Is semaglutide safe for adults over 65?

Yes, based on subgroup analyses showing similar efficacy and tolerability. Older adults require closer monitoring for sarcopenia, falls, dehydration, and drug interactions.

Is there an age cutoff for GLP-1 therapy?

No FDA-defined upper age cutoff. Individual fitness depends on functional status, baseline weight, comorbidities, and patient goals rather than chronological age.

Do older adults lose less weight on Wegovy or Zepbound?

Per-percentage weight loss is similar across age strata. Absolute weight loss tracks with starting weight.

Fall risk on semaglutide?

Modestly elevated due to potential dehydration and orthostasis from GI symptoms, particularly during dose escalation. Maintain fluid intake, rise slowly, and report falls promptly.

Will I lose muscle mass at age 70?

Lean-mass loss with weight reduction is more clinically meaningful in older adults due to lower baseline reserves. Adequate protein (1.2-1.5 g/kg/day) and resistance training mitigate this risk.